Form 4: aTyr Pharma CFO Jill Broadfoot Reports Stock Transactions

Jill Marie Broadfoot, CFO of aTyr Pharma, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Summary

• On February 3, 2025, Jill Marie Broadfoot, the Chief Financial Officer of aTyr Pharma, exercised restricted stock units (RSUs) converting into 3,750 shares of common stock.
• Following the vesting, Broadfoot sold 1,254 shares of common stock on February 4, 2025, at a price of $3.78 per share.
• The sale was made to satisfy tax withholding obligations related to the vesting of the RSUs.
• After these transactions, Broadfoot directly owns 31,763 shares of aTyr Pharma common stock.
• The RSUs were granted on February 3, 2022, and vest in four equal annual installments, with full vesting expected on February 3, 2026.
• Broadfoot also acquired 1,307 shares on November 15, 2024, under the company's 2015 Employee Purchase Plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions related to executive compensation and tax obligations. There's no indication of unusual or concerning activity.

Positives

• The vesting of RSUs indicates that Broadfoot is meeting the conditions of her equity compensation plan.
• Participation in the Employee Purchase Plan shows confidence in the company's future.

Negatives

• The sale of shares, even for tax purposes, could be interpreted negatively by some investors, although it's a common practice.

Risks

• The document does not explicitly mention any risks.
• However, any insider selling activity can sometimes create uncertainty in the market.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Comparing aTyr Pharma to similar biotech companies like Arcus Biosciences or Iovance Biotherapeutics, insider transactions are a common occurrence.
• However, the significance of these transactions depends on the size and frequency of the trades relative to the insider's total holdings and the company's market capitalization.
• For example, if executives at Arcus Biosciences were consistently selling large portions of their holdings, it might raise concerns, whereas routine sales to cover taxes are generally viewed as neutral.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the small volume of shares sold.
• Employees holding aTyr Pharma stock may be interested in the details of the Employee Purchase Plan.

Key Dates

Keywords

aTyr Pharma, Jill Broadfoot, CFO, stock, RSU, restricted stock units, insider trading, Form 4, vesting, employee purchase plan